About: http://data.cimple.eu/news-article/784c19a5998bcf8254f6f87a332415b836c11b243270988100223a69     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • The head of Pfizer said in an interview aired Thursday that people will "likely" need a third dose of his company's Covid-19 vaccine within a year of being fully vaccinated. CEO Albert Bourla also said annual vaccinations against the coronavirus may well be required. "We need to see what would be the sequence, and for how often we need to do that, that remains to be seen," Bourla told CNBC in an interview recorded on April 1. "A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual revaccination, but all of that needs to be confirmed," he said, adding that variants will play a "key role." "It is extremely important to suppress the pool of people that can be susceptible to the virus," he said. Researchers currently don't know how long vaccines provide protection against the coronavirus. Pfizer published a study earlier this month that said its jab is more than 91 percent effective at protecting against the coronavirus, and more than 95 percent effective against severe cases of Covid-19 up to six months after the second dose. But researchers say more data is needed to determine whether protection lasts after six months. David Kessler, the head of US President Joe Biden's Covid-19 response team, warned a congressional committee on Thursday that Americans should expect to receive booster shots to defend against coronavirus variants. "We don't know everything at this moment," he told the House Coronavirus Crisis Subcommittee. "We are studying the durability of the antibody response. "It seems strong but there is some waning of that and no doubt the variants challenge," he said. "I think for planning purposes, planning purposes only, I think we should expect that we may have to boost." The Pfizer vaccine, developed in partnership with German firm BioNTech, currently plays a leading role in American and European vaccination campaigns. The pharmaceutical giant announced in February that it was testing a third dose of its vaccine to better combat the emerging variants. to/acb
schema:headline
  • Pfizer CEO: Vaccine third dose 'likely' needed within 12 months
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software